1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Bladder cancer

Pembrolizumab adjuvant for urothelial carcinoma and/or localised muscle invasive bladder cancer TSID 12021

Awaiting development [GID-TA11556] Expected publication date: TBC

  • Project information
  • Project documents

38268-Pembrolizumab-for-Urothelial-Carcinoma-V1.0-MAR2024-NON-CONF.pdf (nihr.ac.uk)